Overview of Dr. Danila
Dr. Daniel Danila is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Carol Davila University of Medicine and Pharmacy and has been in practice 21 years. Dr. Danila accepts several types of health insurance, listed below. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 80 publications and over 500 citings.
Office
353 East 68th Street
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2009
Massachusetts General HospitalResidency, Internal Medicine, 2002 - 2005
Carol Davila University of Medicine and PharmacyClass of 1996
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2005 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2018 - 2025
NC State Medical License 2020 - 2022
MA State Medical License 2004 - 2019- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2011 Mar 01
- Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2012 Sep 01
Publications & Presentations
PubMed
- 1022 citationsOrganoid cultures derived from patients with advanced prostate cancerDong Gao, Ian Vela, Andrea Sboner, Phillip J. Iaquinta, Wouter R. Karthaus
Cell. 2014-09-25 - 1431 citationsOncoKB: A Precision Oncology Knowledge Base.Debyani Chakravarty, Jianjiong Gao, Sarah Fierberg Phillips, Ritika Kundra, Hongxin Zhang
JCO Precision Oncology. 2017-05-16 - 791 citationsAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.Howard I. Scher, Tomasz M. Beer, Celestia S. Higano, Aseem Anand, Mary-Ellen Taplin
Lancet. 2010-04-24
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPOGreat West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
PriorityHealth HMO
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
